Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acumen Pharmaceuticals, Inc.

http://www.acumenpharm.com/

Latest From Acumen Pharmaceuticals, Inc.

IPO Update: Booming Biopharma On Pace For Another Record Year

Only 25 more initial public offerings are needed for 2021 to beat 2020’s record-breaking 86 IPOs. However, the average return for this year’s offerings is just 1.1% as of 1 July versus 11% at the end of the first quarter.

Financing Business Strategies

Finance Watch: Five Biopharma IPOs Bring US Total To 60 In 2021

Public Company Edition: Almost halfway through the year, initial public offerings equal nearly three-quarters of the 2020 total. Also, Pardes is one of four new SPAC mergers; HUTCHMED launched an IPO in Hong Kong; and Zentalis, Theravance and BioXcel launched follow-on offerings.

Financing Growth

Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor

New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.

Deals Business Strategies

Venture Funding Deals: Recent Rounds For Gene-Editing Plays Top $300m

Gene-editing focused start-ups Beam Therapeutics, Gracell, Snipr Biome and Precision Biosciences raised a total of $310m in financings in February and March. For other recent venture funding deals... 

Deals Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register